HK1195736A1 - 放射免疫偶聯物和它們的用途 - Google Patents

放射免疫偶聯物和它們的用途

Info

Publication number
HK1195736A1
HK1195736A1 HK14109175.2A HK14109175A HK1195736A1 HK 1195736 A1 HK1195736 A1 HK 1195736A1 HK 14109175 A HK14109175 A HK 14109175A HK 1195736 A1 HK1195736 A1 HK 1195736A1
Authority
HK
Hong Kong
Prior art keywords
radioimmunoconjugates
Prior art date
Application number
HK14109175.2A
Other languages
English (en)
Inventor
Roy H Larsen
Jostein Dahle
Yvind S Bruland
Original Assignee
Nordic Nanovector Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector Asa filed Critical Nordic Nanovector Asa
Publication of HK1195736A1 publication Critical patent/HK1195736A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK14109175.2A 2010-01-29 2014-09-11 放射免疫偶聯物和它們的用途 HK1195736A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav

Publications (1)

Publication Number Publication Date
HK1195736A1 true HK1195736A1 (zh) 2014-11-21

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13106111.6A HK1179157A1 (en) 2010-01-29 2013-05-23 Radioimmunoconjugates and uses thereof
HK14109175.2A HK1195736A1 (zh) 2010-01-29 2014-09-11 放射免疫偶聯物和它們的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13106111.6A HK1179157A1 (en) 2010-01-29 2013-05-23 Radioimmunoconjugates and uses thereof

Country Status (26)

Country Link
US (2) US8628749B2 (zh)
EP (2) EP2528627B1 (zh)
JP (2) JP5646652B2 (zh)
KR (2) KR101758409B1 (zh)
CN (2) CN102762230B (zh)
AU (1) AU2011209441B2 (zh)
BR (1) BR112012018843B8 (zh)
CA (1) CA2786655C (zh)
DK (2) DK2705857T3 (zh)
ES (2) ES2592402T3 (zh)
HK (2) HK1179157A1 (zh)
HR (1) HRP20140538T1 (zh)
IL (2) IL221091A (zh)
MX (2) MX342539B (zh)
NO (1) NO331080B1 (zh)
NZ (1) NZ601055A (zh)
PH (1) PH12017501038B1 (zh)
PL (1) PL2528627T3 (zh)
PT (1) PT2528627E (zh)
RS (1) RS53346B (zh)
RU (2) RU2560587C9 (zh)
SG (1) SG182685A1 (zh)
SI (1) SI2528627T1 (zh)
UA (1) UA108631C2 (zh)
WO (1) WO2011092295A2 (zh)
ZA (1) ZA201205007B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2658438C2 (ru) * 2011-12-13 2018-06-21 Нордик Нановектор Аса Химерное терапевтическое антитело нн1 против cd-37
BR112014024487A2 (pt) * 2012-03-30 2017-08-08 Immunogen Inc métodos para aumentar a eficácia da terapia baseada em cd37
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
KR102033819B1 (ko) * 2013-06-07 2019-10-17 노르딕 나노벡터 에이에스에이 상향조절 항원 발현 방법
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
EP3280454A1 (en) * 2015-04-07 2018-02-14 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
KR20190054113A (ko) * 2016-09-16 2019-05-21 노르딕 나노벡터 에이에스에이 릴로토맙 및 177Lu-릴로토맙 사테트라세탄을 이용한 비-호지킨 림프종의 치료
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
EP3713607A1 (en) * 2017-11-22 2020-09-30 Nordic Nanovector ASA Radioimmunoconjugates in combination with other drugs as treatment against nhl
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU5914201A (en) * 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1569690B1 (en) * 2002-12-13 2011-07-27 Mitra Medical Technology AB Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
ATE517638T1 (de) * 2003-01-31 2011-08-15 Immunomedics Inc Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
US9358309B2 (en) 2016-06-07
JP2015057415A (ja) 2015-03-26
JP2013518086A (ja) 2013-05-20
WO2011092295A2 (en) 2011-08-04
RU2560587C2 (ru) 2015-08-20
BR112012018843A8 (pt) 2017-12-19
PH12017501038A1 (en) 2017-12-11
BR112012018843A2 (pt) 2017-10-17
KR20130028051A (ko) 2013-03-18
HK1179157A1 (en) 2013-09-27
CN104338154B (zh) 2017-09-22
RU2560587C9 (ru) 2015-11-27
EP2528627A2 (en) 2012-12-05
EP2705857B1 (en) 2016-06-22
DK2705857T3 (en) 2016-08-29
IL221091A0 (en) 2012-09-24
US20140147384A1 (en) 2014-05-29
ES2592402T3 (es) 2016-11-30
AU2011209441B2 (en) 2016-03-03
KR101893720B1 (ko) 2018-08-30
KR101758409B1 (ko) 2017-07-14
IL237507A0 (en) 2015-04-30
AU2011209441A1 (en) 2012-07-19
CA2786655C (en) 2016-12-13
SI2528627T1 (sl) 2014-08-29
NZ601055A (en) 2013-12-20
ZA201205007B (en) 2013-09-25
PH12017501038B1 (en) 2017-12-11
ES2469140T3 (es) 2014-06-17
RU2012135430A (ru) 2014-03-10
UA108631C2 (xx) 2015-05-25
NO331080B1 (no) 2011-09-26
CN102762230B (zh) 2014-08-13
HRP20140538T1 (hr) 2014-07-18
PT2528627E (pt) 2014-06-12
US20120301396A1 (en) 2012-11-29
MX342539B (es) 2016-10-04
JP5646652B2 (ja) 2014-12-24
RS53346B (en) 2014-10-31
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
BR112012018843B8 (pt) 2020-12-22
EP2705857A2 (en) 2014-03-12
EP2528627B1 (en) 2014-03-19
CN104338154A (zh) 2015-02-11
IL221091A (en) 2015-03-31
NO20100143A1 (no) 2011-08-01
US8628749B2 (en) 2014-01-14
WO2011092295A3 (en) 2011-11-24
CN102762230A (zh) 2012-10-31
EP2705857A3 (en) 2014-07-30
CA2786655A1 (en) 2011-08-04
MX2012008695A (es) 2012-11-23
BR112012018843B1 (pt) 2020-09-24
JP5855209B2 (ja) 2016-02-09
DK2528627T3 (da) 2014-05-12
KR20170084349A (ko) 2017-07-19
PL2528627T3 (pl) 2014-08-29

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HK1187049A1 (zh) 雙芳基連接的芳基三唑酮及其用途
HK1195736A1 (zh) 放射免疫偶聯物和它們的用途
ZA201208173B (en) Peptices and their use
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
ZA201303773B (en) Compounds and their use
HRP20182083T1 (hr) Nova kombinacija i uporaba
EP2575453A4 (en) OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE
GB201011411D0 (en) Therapeutic compounds and their use
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2615094A4 (en) SESTERTERPEN COMPOUNDS AND THEIR USE
GB201020848D0 (en) Compounds and their use
GB201018028D0 (en) Compounds and their use
GB201017822D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201002337D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use
GB201000305D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230201